FDA Rejects Akeso's Ivonescimab, Citing China-Heavy Trial Data
The FDA refused to approve ivonescimab for EGFR-mutated lung cancer, saying 93% of the trial's cancer progressions and deaths came from patients enrolled in China. Summit Therapeutics, Akeso's US partner, disclosed the 13 November letter on 15 November; Akeso shares closed 22% lower in Hong Kong the next day.
- Original source: ruibao.news.
- The source published it on Nov 21, 2026 at 11:26 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA handed Summit Therapeutics a complete response letter dated 13 November, rejecting ivonescimab as a treatment for advanced non-small cell lung cancer with an EGFR mutation that has stopped responding to targeted pills. Of 275 cancer progressions or deaths in the HARMONi trial, 257 happened in patients enrolled in China — 93%. The agency said it could not tell whether the result would hold for Americans. Summit announced the decision on the evening of 15 November, Singapore time, and the FDA later posted the letter online with passages blacked out.
The rejection also turned on efficacy. Median progression-free survival was 6.8 months on ivonescimab versus 4.4 months on chemotherapy alone, a 48% lower risk of the cancer worsening or death, while half the ivonescimab patients lived beyond 16.8 months against 14.0 months. That 2.8-month survival gap missed the statistical bar set before the trial started. Tumours shrank substantially in 44.7% of patients on the drug and 34.2% on chemotherapy — a difference the FDA called not substantial. The letter says the modest PFS improvement does not outweigh risks including serious immune-related side effects and others tied to blocking VEGF. Summit countered that 7.3% of ivonescimab patients stopped treatment over side effects, against 5.0% on placebo.
Summit also pointed to longer follow-up released on 22 July 2026, showing roughly a 24% lower risk of death on ivonescimab both across the trial and among Western patients, with data to June 2026 — though Asian patient data stayed frozen at April 2025. The FDA dismissed those figures as exploratory, after-the-fact analyses and flagged that data were cut off at different times by region, apparently because Chinese sites closed during 2025 and follow-up ended there earlier. Summit said it had shared the July numbers with the agency.
The enrolment problem was flagged early. HARMONi began recruiting in China in January 2022, and by November 2022 Chinese patients made up 60% of the eventual trial. At a March 2023 meeting the FDA raised concerns, and recruitment in North America and the European Union began two months later. The trial ultimately enrolled 438 patients, 165 of them from North America and Europe. The agency repeated its concerns at a May 2025 pre-filing meeting. Summit filed on 14 November 2025, and the July follow-up showed Western patients had been tracked for a median of only 9.2 months at the April 2025 cut-off.
Markets reacted hard. Akeso shares closed 22% lower at HK$64.10 in Hong Kong on 16 November; the board said it knew of no reason for the unusual trading beyond the letter. The same day, the trustee of an Akeso share award scheme bought 336,000 shares for about HK$21 million. Summit closed at $11.82 in New York, down 16%. On an investor call, Akeso chair Xia Yu said the companies had persuaded the FDA to accept the China-first design, and that the agency wanted a statistically significant survival result from the start, according to Fierce Biotech.
Debate over the standard spilled onto Chinese investor forum Xueqiu. A post by Pifu Hancong compared the case to Johnson & Johnson's Rybrevant, saying it won approval for the same patients without a survival result, and argued Chinese drugmakers face a different review. Writer Rui Bio pushed back, saying Rybrevant's final survival analysis became a post-approval requirement while ivonescimab's formal survival test was complete and had failed. On 20 November, The Paper, citing the Financial Times, said some US politicians had pressed the FDA against accepting Chinese trial data, pointing to an August letter from John Moolenaar and Representative Ben Cline urging rejection of such data absent in-person site inspections within 12 months. Summit now has a year to resubmit, with worldwide safety data, or seek more time.
TopicsFDA · Akeso · Summit Therapeutics · ivonescimab · HARMONi · Xia Yu · Rybrevant · John Moolenaar
Source: ruibao.news
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 1 viewCompass Pathways bets on fast FDA review for psilocybin depression drug
- Health & science theguardian.com Caught by @pipio 2 viewsTrusted Messengers Hold the Key to Stopping the Amish Measles Outbreak
- Health & science simplywall.st 2 sources 2 viewsAlnylam Notches Seventh FDA Approval as Livsayis Clears Myasthenia Gravis
- Health & science sciencealert.com Caught by @ajayy30 1 viewKids With More Screen Time Scored Better on Teen Brain Tests, 8-Year Study Finds

